1. Academic Validation
  2. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development

  • Cell. 2001 Nov 16;107(4):513-23. doi: 10.1016/s0092-8674(01)00571-2.
Y Gong R B Slee N Fukai G Rawadi S Roman-Roman A M Reginato H Wang T Cundy F H Glorieux D Lev M Zacharin K Oexle J Marcelino W Suwairi S Heeger G Sabatakos S Apte W N Adkins J Allgrove M Arslan-Kirchner J A Batch P Beighton G C Black R G Boles L M Boon C Borrone H G Brunner G F Carle B Dallapiccola A De Paepe B Floege M L Halfhide B Hall R C Hennekam T Hirose A Jans H Jüppner C A Kim K Keppler-Noreuil A Kohlschuetter D LaCombe M Lambert E Lemyre T Letteboer L Peltonen R S Ramesar M Romanengo H Somer E Steichen-Gersdorf B Steinmann B Sullivan A Superti-Furga W Swoboda M J van den Boogaard W Van Hul M Vikkula M Votruba B Zabel T Garcia R Baron B R Olsen M L Warman Osteoporosis-Pseudoglioma Syndrome Collaborative Group
Abstract

In humans, low peak bone mass is a significant risk factor for osteoporosis. We report that LRP5, encoding the low-density lipoprotein receptor-related protein 5, affects bone mass accrual during growth. Mutations in LRP5 cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome (OPPG). We find that OPPG carriers have reduced bone mass when compared to age- and gender-matched controls. We demonstrate LRP5 expression by osteoblasts in situ and show that LRP5 can transduce Wnt signaling in vitro via the canonical pathway. We further show that a mutant-secreted form of LRP5 can reduce bone thickness in mouse calvarial explant cultures. These data indicate that Wnt-mediated signaling via LRP5 affects bone accrual during growth and is important for the establishment of peak bone mass.

Figures